Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[18F]PI-2620 PET Imaging in Tauopathies
NCT03510572Phase 1Completed
- Sponsor
- Asan Medical Center
- Start
- Jun 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-PI-2620 in Alzheimer's disease (AD), frontotemporal dementia (FTD) and Parkinson's disease (PD) (4 arms), sponsored by Asan Medical Center. Primary endpoints: [18F]PI-2620 Imaging Results and Rate of change of tau deposition. Started Jun 2018; status: completed.
02
Drugs
18F-PI-2620
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03510572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03510572.